Sunitinib paves the way for targeted therapies in neuroendocrine tumors View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2009-11-13

AUTHORS

Eric Raymond, Sandrine Faivre, Pascal Hammel, Philippe Ruszniewski

ABSTRACT

Sunitinib demonstrating efficacy in pancreatic islet cell carcinomas will pave the way for further trials in other neuroendocrine tumor types such as carcinoid, poorly differentiated neuroendocrine disease, and several other endocrine tumors that are dependent on VEGF/VEGFR for angiogenesis. In addition, other drugs with distinct mechanisms of action, such as mTOR inhibitors, currently investigated in phase III trials, may also supply novel options in those diseases to control tumor growth and metastasis. More... »

PAGES

253

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11523-009-0130-0

DOI

http://dx.doi.org/10.1007/s11523-009-0130-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1047545273

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19911111


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoid Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ErbB Receptors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melphalan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neovascularization, Pathologic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neuroendocrine Tumors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Procarbazine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-kit", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrroles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sunitinib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vinblastine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Xenograft Model Antitumor Assays", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Service Inter-Hospitalier de Canc\u00e9rologie Beaujon-Bichat, H\u00f4pital Beaujon AP-HP, 100, boulevard du g\u00e9n\u00e9ral Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Department of Medical Oncology and Gastroenterology, Beaujon University Hospital, Clichy, France", 
            "Service Inter-Hospitalier de Canc\u00e9rologie Beaujon-Bichat, H\u00f4pital Beaujon AP-HP, 100, boulevard du g\u00e9n\u00e9ral Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Raymond", 
        "givenName": "Eric", 
        "id": "sg:person.0722574726.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722574726.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology and Gastroenterology, Beaujon University Hospital, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Department of Medical Oncology and Gastroenterology, Beaujon University Hospital, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Faivre", 
        "givenName": "Sandrine", 
        "id": "sg:person.01026352014.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026352014.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology and Gastroenterology, Beaujon University Hospital, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Department of Medical Oncology and Gastroenterology, Beaujon University Hospital, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hammel", 
        "givenName": "Pascal", 
        "id": "sg:person.01355345644.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355345644.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology and Gastroenterology, Beaujon University Hospital, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Department of Medical Oncology and Gastroenterology, Beaujon University Hospital, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ruszniewski", 
        "givenName": "Philippe", 
        "id": "sg:person.0640551545.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640551545.21"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/00002018-200932090-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046797294", 
          "https://doi.org/10.2165/00002018-200932090-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd2380", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044070644", 
          "https://doi.org/10.1038/nrd2380"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6602245", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012438597", 
          "https://doi.org/10.1038/sj.bjc.6602245"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-11-13", 
    "datePublishedReg": "2009-11-13", 
    "description": "Sunitinib demonstrating efficacy in pancreatic islet cell carcinomas will pave the way for further trials in other neuroendocrine tumor types such as carcinoid, poorly differentiated neuroendocrine disease, and several other endocrine tumors that are dependent on VEGF/VEGFR for angiogenesis. In addition, other drugs with distinct mechanisms of action, such as mTOR inhibitors, currently investigated in phase III trials, may also supply novel options in those diseases to control tumor growth and metastasis.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11523-009-0130-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1036678", 
        "issn": [
          "1776-2596", 
          "1776-260X"
        ], 
        "name": "Targeted Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "4"
      }
    ], 
    "keywords": [
      "pancreatic islet cell carcinoma", 
      "phase III trials", 
      "islet cell carcinoma", 
      "neuroendocrine tumor types", 
      "VEGF/VEGFR", 
      "III trials", 
      "cell carcinoma", 
      "neuroendocrine disease", 
      "endocrine tumors", 
      "neuroendocrine tumors", 
      "further trials", 
      "mTOR inhibitors", 
      "tumor types", 
      "tumor growth", 
      "novel option", 
      "tumors", 
      "disease", 
      "trials", 
      "distinct mechanisms", 
      "sunitinib", 
      "carcinoma", 
      "metastasis", 
      "therapy", 
      "VEGFR", 
      "drugs", 
      "efficacy", 
      "angiogenesis", 
      "inhibitors", 
      "options", 
      "action", 
      "mechanism", 
      "addition", 
      "types", 
      "growth", 
      "way"
    ], 
    "name": "Sunitinib paves the way for targeted therapies in neuroendocrine tumors", 
    "pagination": "253", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1047545273"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11523-009-0130-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19911111"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11523-009-0130-0", 
      "https://app.dimensions.ai/details/publication/pub.1047545273"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_484.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11523-009-0130-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11523-009-0130-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11523-009-0130-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11523-009-0130-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11523-009-0130-0'


 

This table displays all metadata directly associated to this object as RDF triples.

228 TRIPLES      22 PREDICATES      88 URIs      77 LITERALS      31 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11523-009-0130-0 schema:about N07c610c4e52c4574b30f1d5ea61fc1d8
2 N0b3692ad58944fb290830518a7038fa0
3 N24d020f49faf417fb16a22c50965f450
4 N27beb7de7dfb4532807934b920f8c9b9
5 N2e5b7780dbcb4f66b7f1945a72fdf91a
6 N2fb4689cc7324f2fb93690e483c1cffe
7 N311aa4a4a9dc413ba82498d6fbc6cb78
8 N334d1da07c6648969def0ab48d7d01c4
9 N3cdc02bd18fc4705b4ab09f225a8d94d
10 N557d0ced55dd4e8db398832045ac3512
11 N5646487b131a43cca6c867a4fd2ca818
12 N7f8f3c63fae74e788e3a20bea6074eb0
13 N82de299e94ee46bd8e19b13d043524a4
14 N874acaf6cd664dfea0b3f57763f590b7
15 N964715a9e2cc403fadd797d8b0144975
16 Na08ae06ee3b74a1ebc712ac8219daa86
17 Na61da04c5af24442b1df7e8a2676e1a8
18 Nb039bbbcd2b249b4aad3a9157207df93
19 Nb886d00d9f1649bf9c86423862a64527
20 Nbe67f0b2b4a64850bfce1e914b3cdc18
21 Ncc93918d5f2e48f38b8430458d2ea8bd
22 Nd8006ac0c6a24b1e8437628ea537b3b5
23 Nd80c7b8c0f2d4c17bbbe33dbc3dfe702
24 Nf1294ac24177458589ca910c3957f1d8
25 anzsrc-for:11
26 anzsrc-for:1112
27 schema:author Ne94da0d4534d494c9ee423e6d83d83a1
28 schema:citation sg:pub.10.1038/nrd2380
29 sg:pub.10.1038/sj.bjc.6602245
30 sg:pub.10.2165/00002018-200932090-00003
31 schema:datePublished 2009-11-13
32 schema:datePublishedReg 2009-11-13
33 schema:description Sunitinib demonstrating efficacy in pancreatic islet cell carcinomas will pave the way for further trials in other neuroendocrine tumor types such as carcinoid, poorly differentiated neuroendocrine disease, and several other endocrine tumors that are dependent on VEGF/VEGFR for angiogenesis. In addition, other drugs with distinct mechanisms of action, such as mTOR inhibitors, currently investigated in phase III trials, may also supply novel options in those diseases to control tumor growth and metastasis.
34 schema:genre article
35 schema:inLanguage en
36 schema:isAccessibleForFree true
37 schema:isPartOf N08552dff8a4c462b9de1052f6bd447ed
38 Nbc4268dc08264c37bec3539d2b080a48
39 sg:journal.1036678
40 schema:keywords III trials
41 VEGF/VEGFR
42 VEGFR
43 action
44 addition
45 angiogenesis
46 carcinoma
47 cell carcinoma
48 disease
49 distinct mechanisms
50 drugs
51 efficacy
52 endocrine tumors
53 further trials
54 growth
55 inhibitors
56 islet cell carcinoma
57 mTOR inhibitors
58 mechanism
59 metastasis
60 neuroendocrine disease
61 neuroendocrine tumor types
62 neuroendocrine tumors
63 novel option
64 options
65 pancreatic islet cell carcinoma
66 phase III trials
67 sunitinib
68 therapy
69 trials
70 tumor growth
71 tumor types
72 tumors
73 types
74 way
75 schema:name Sunitinib paves the way for targeted therapies in neuroendocrine tumors
76 schema:pagination 253
77 schema:productId N417fd19a94224d3fb5de53e549025549
78 Ncd8230d812d940888dd907b29f4326a3
79 Nd8b6bbd4d3644a6aba211f58af75f223
80 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047545273
81 https://doi.org/10.1007/s11523-009-0130-0
82 schema:sdDatePublished 2021-11-01T18:13
83 schema:sdLicense https://scigraph.springernature.com/explorer/license/
84 schema:sdPublisher N5c305f59964843c4b179ebe4ec73b05e
85 schema:url https://doi.org/10.1007/s11523-009-0130-0
86 sgo:license sg:explorer/license/
87 sgo:sdDataset articles
88 rdf:type schema:ScholarlyArticle
89 N07c610c4e52c4574b30f1d5ea61fc1d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Neovascularization, Pathologic
91 rdf:type schema:DefinedTerm
92 N08552dff8a4c462b9de1052f6bd447ed schema:issueNumber 4
93 rdf:type schema:PublicationIssue
94 N0b3692ad58944fb290830518a7038fa0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Xenograft Model Antitumor Assays
96 rdf:type schema:DefinedTerm
97 N24d020f49faf417fb16a22c50965f450 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Vinblastine
99 rdf:type schema:DefinedTerm
100 N27beb7de7dfb4532807934b920f8c9b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Pyrroles
102 rdf:type schema:DefinedTerm
103 N2e5b7780dbcb4f66b7f1945a72fdf91a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Proto-Oncogene Proteins c-kit
105 rdf:type schema:DefinedTerm
106 N2fb4689cc7324f2fb93690e483c1cffe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Melphalan
108 rdf:type schema:DefinedTerm
109 N311aa4a4a9dc413ba82498d6fbc6cb78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Humans
111 rdf:type schema:DefinedTerm
112 N334d1da07c6648969def0ab48d7d01c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Indoles
114 rdf:type schema:DefinedTerm
115 N3cdc02bd18fc4705b4ab09f225a8d94d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Kidney Neoplasms
117 rdf:type schema:DefinedTerm
118 N417fd19a94224d3fb5de53e549025549 schema:name pubmed_id
119 schema:value 19911111
120 rdf:type schema:PropertyValue
121 N557d0ced55dd4e8db398832045ac3512 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Angiogenesis Inhibitors
123 rdf:type schema:DefinedTerm
124 N5646487b131a43cca6c867a4fd2ca818 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Carcinoid Tumor
126 rdf:type schema:DefinedTerm
127 N5c305f59964843c4b179ebe4ec73b05e schema:name Springer Nature - SN SciGraph project
128 rdf:type schema:Organization
129 N7f8f3c63fae74e788e3a20bea6074eb0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Pancreatic Neoplasms
131 rdf:type schema:DefinedTerm
132 N82de299e94ee46bd8e19b13d043524a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Biomarkers, Tumor
134 rdf:type schema:DefinedTerm
135 N874acaf6cd664dfea0b3f57763f590b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Drug Resistance, Neoplasm
137 rdf:type schema:DefinedTerm
138 N964715a9e2cc403fadd797d8b0144975 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Dose-Response Relationship, Drug
140 rdf:type schema:DefinedTerm
141 N99b2fa2e83024243a683423464e7a335 rdf:first sg:person.01355345644.55
142 rdf:rest Nb1801d671db242a08bfc29551bea9b0e
143 Na08ae06ee3b74a1ebc712ac8219daa86 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Clinical Trials as Topic
145 rdf:type schema:DefinedTerm
146 Na61da04c5af24442b1df7e8a2676e1a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Cell Line, Tumor
148 rdf:type schema:DefinedTerm
149 Nb039bbbcd2b249b4aad3a9157207df93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name ErbB Receptors
151 rdf:type schema:DefinedTerm
152 Nb1801d671db242a08bfc29551bea9b0e rdf:first sg:person.0640551545.21
153 rdf:rest rdf:nil
154 Nb886d00d9f1649bf9c86423862a64527 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Protein Kinase Inhibitors
156 rdf:type schema:DefinedTerm
157 Nbc4268dc08264c37bec3539d2b080a48 schema:volumeNumber 4
158 rdf:type schema:PublicationVolume
159 Nbe67f0b2b4a64850bfce1e914b3cdc18 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Neuroendocrine Tumors
161 rdf:type schema:DefinedTerm
162 Ncc93918d5f2e48f38b8430458d2ea8bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Procarbazine
164 rdf:type schema:DefinedTerm
165 Ncd8230d812d940888dd907b29f4326a3 schema:name doi
166 schema:value 10.1007/s11523-009-0130-0
167 rdf:type schema:PropertyValue
168 Nd8006ac0c6a24b1e8437628ea537b3b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Antineoplastic Combined Chemotherapy Protocols
170 rdf:type schema:DefinedTerm
171 Nd80c7b8c0f2d4c17bbbe33dbc3dfe702 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Lung Neoplasms
173 rdf:type schema:DefinedTerm
174 Nd8b6bbd4d3644a6aba211f58af75f223 schema:name dimensions_id
175 schema:value pub.1047545273
176 rdf:type schema:PropertyValue
177 Ne94da0d4534d494c9ee423e6d83d83a1 rdf:first sg:person.0722574726.55
178 rdf:rest Nfeb2e11b77bb4b6c9f03c595583122ba
179 Nf1294ac24177458589ca910c3957f1d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Sunitinib
181 rdf:type schema:DefinedTerm
182 Nfeb2e11b77bb4b6c9f03c595583122ba rdf:first sg:person.01026352014.76
183 rdf:rest N99b2fa2e83024243a683423464e7a335
184 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
185 schema:name Medical and Health Sciences
186 rdf:type schema:DefinedTerm
187 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
188 schema:name Oncology and Carcinogenesis
189 rdf:type schema:DefinedTerm
190 sg:journal.1036678 schema:issn 1776-2596
191 1776-260X
192 schema:name Targeted Oncology
193 schema:publisher Springer Nature
194 rdf:type schema:Periodical
195 sg:person.01026352014.76 schema:affiliation grid-institutes:grid.411599.1
196 schema:familyName Faivre
197 schema:givenName Sandrine
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026352014.76
199 rdf:type schema:Person
200 sg:person.01355345644.55 schema:affiliation grid-institutes:grid.411599.1
201 schema:familyName Hammel
202 schema:givenName Pascal
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355345644.55
204 rdf:type schema:Person
205 sg:person.0640551545.21 schema:affiliation grid-institutes:grid.411599.1
206 schema:familyName Ruszniewski
207 schema:givenName Philippe
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640551545.21
209 rdf:type schema:Person
210 sg:person.0722574726.55 schema:affiliation grid-institutes:grid.411599.1
211 schema:familyName Raymond
212 schema:givenName Eric
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722574726.55
214 rdf:type schema:Person
215 sg:pub.10.1038/nrd2380 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044070644
216 https://doi.org/10.1038/nrd2380
217 rdf:type schema:CreativeWork
218 sg:pub.10.1038/sj.bjc.6602245 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012438597
219 https://doi.org/10.1038/sj.bjc.6602245
220 rdf:type schema:CreativeWork
221 sg:pub.10.2165/00002018-200932090-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046797294
222 https://doi.org/10.2165/00002018-200932090-00003
223 rdf:type schema:CreativeWork
224 grid-institutes:grid.411599.1 schema:alternateName Department of Medical Oncology and Gastroenterology, Beaujon University Hospital, Clichy, France
225 Service Inter-Hospitalier de Cancérologie Beaujon-Bichat, Hôpital Beaujon AP-HP, 100, boulevard du général Leclerc, 92110, Clichy, France
226 schema:name Department of Medical Oncology and Gastroenterology, Beaujon University Hospital, Clichy, France
227 Service Inter-Hospitalier de Cancérologie Beaujon-Bichat, Hôpital Beaujon AP-HP, 100, boulevard du général Leclerc, 92110, Clichy, France
228 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...